How do bisphosphonates inhibit bone metastasis in vivo?

Area of Science:

• Oncology
• Pharmacology
• Bone Biology

Background:

• Bisphosphonates treat osteolytic bone metastases by inhibiting osteoclast-mediated bone resorption.
• Bisphosphonates show in vitro antitumor activity, but their in vivo mechanism (direct vs. indirect) is debated.

Purpose of the Study:

• To differentiate the direct antitumor effects of bisphosphonates from their indirect effects via bone resorption inhibition.
• To investigate the role of osteoclast inhibition in the efficacy of bisphosphonates against bone metastases.

Main Methods:

• Utilized NE-58051, a risedronate analog with similar bone affinity but significantly lower antiresorptive activity.
• Assessed in vitro proliferation of breast cancer and melanoma cell lines with risedronate and NE-58051.
• Evaluated in vivo effects on subcutaneous breast tumor xenografts and melanoma lung metastasis formation.
• Examined the impact on B02 breast cancer bone metastasis formation, including bone destruction and tumor burden.

Main Results:

• Both risedronate and NE-58051 inhibited cancer cell proliferation in vitro.
• Neither compound affected subcutaneous breast tumor xenograft growth or melanoma lung metastasis in vivo.
• Risedronate, but not NE-58051, inhibited breast cancer bone metastasis formation.
• Risedronate reduced bone destruction and skeletal tumor burden in the bone metastasis model.

Conclusions:

• The primary antitumor effect of bisphosphonates in bone metastases is mediated by the inhibition of osteoclast-mediated bone resorption.
• Direct cytotoxic effects of bisphosphonates on tumor cells appear less significant in vivo compared to their impact on the bone microenvironment.